Why Probiotic Trials Disagree: Strain, Dose, Population and Outcome Differences
Why probiotic studies give different answers: the strain or product, the number of live organisms, who was studied, what was measured, and how well the trial was run.
Content last updated . This page has not been medically reviewed.
This page teaches how to read the conflict. It does not rank products or say which result is right, and it is information only.
Evidence labels on this page
- Mixed: well-run studies point in different directions, or results depend on the product and group studied.
- Insufficient: too few or too weak studies to say.
- Study amount: the number of live organisms (colony-forming units, CFU) used in a trial. It describes what was tested, never what to take.
- Proper evidence not found: we looked in the sources named and found nothing usable.
Six reasons results differ
| Reason | What differs | What the sources we read say |
|---|---|---|
| The product | Strain, mix of strains, or a combination product | NCCIH: if one kind of Lactobacillus helps prevent an illness, that does not necessarily mean another kind of Lactobacillus or any of the Bifidobacterium probiotics would do the same thing. [1] The FDA noted different probiotics were used in different trials. [2] |
| Live count and viability | CFU at the start, middle and end of a trial; how the strain was described | A 2012 symposium report listed, as good practice, showing viability at the beginning, middle and end of a study and describing the strain in detail. [3] A 2014 expert panel said products too often lack defined contents and an appropriate viable count at end of shelf-life. [4] |
| The people studied | Age, health, illness being treated, cause of illness, setting | The 2020 AGA technical review of trials for preventing C. difficile-associated diarrhea after antibiotics found baseline populations were remarkably heterogeneous: children, adults and the elderly, inpatients and outpatients. [5] A travelers' diarrhea guideline noted studies vary in strains used, causes of the diarrhea and locations. [1] |
| The outcome | What was counted and when | Reviews of probiotics for constipation in children found the studies hard to compare because of differences in the children studied and the types of probiotics used. [1] |
| Study quality and reporting | Blinding, drop-outs, selective reporting | In the same AGA review, only 2 of the 39 studies had low risk of bias across all domains for all outcomes assessed. [5] The reviewers also flagged potential publication bias, given many registered trial protocols with no matching peer-reviewed publication. [5] |
| How results are combined | Pooling different strains into one analysis, or splitting by strain | The reviewers lowered their certainty rating when trials disagreed (inconsistency), measured something slightly different (indirectness) or were small (imprecision). [5] They also ran subgroup analyses for individual species and strains. [5] |
Some of these are a genuine disagreement and some are only a difference in what was tested. A 2012 report also noted that probiotic trials can be confounded by the health status of the consumers and their resident microbiota. [3]
A worked example: two trials in children with gastroenteritis
Both trials were published in the same 2018 journal issue. Both used a placebo, both enrolled young children seen in emergency departments with gastroenteritis, and both reported no difference from placebo on their main outcome.| Detail | Trial 1 | Trial 2 |
|---|---|---|
| Product | Lactobacillus rhamnosus GG | A combination of L. rhamnosus R0011 and L. helveticus R0052 |
| Study amount | 1 x 10^10 CFU twice daily for 5 days [6] | 4.0 x 10^9 CFU twice daily for 5 days [7] |
| People | 971 children aged 3 months to 4 years, 10 US pediatric emergency departments | 886 children aged 3 to 48 months, six Canadian pediatric emergency departments |
| Main outcome | Moderate-to-severe gastroenteritis within 14 days (modified Vesikari score of 9 or higher) | The same scale and cutoff within 14 days |
| Result | 11.8% with probiotic vs 12.6% with placebo [6] | 26.1% with probiotic vs 24.7% with placebo [7] |
These two results agree with each other, yet they would be misread if applied elsewhere. They say nothing about adults taking antibiotics, or about other strains, or about outcomes other than severity of gastroenteritis. The AGA review described the overall evidence for preventing C. difficile-associated diarrhea after antibiotic use as promising for probiotics in general and for certain strains and combinations in particular. [5] That is a different populations, outcomes and products, so neither finding cancels the other. For more on that condition, see Probiotics for antibiotic-associated diarrhea.
How to read a probiotic headline
- Which exact strain or product was tested? See Strain specificity.
- What was the study amount, for how long, and was the live count confirmed?
- Who took part, and are they like you or like someone you are asking about?
- Was there a placebo or usual-care comparison?
- Was the outcome something a person feels (symptoms, illness) or a lab measure? Do not treat a lab change as a health result.
- Was it one small trial or a pooled review, and did the reviewers rate their certainty?
Broader reading help is in Supplement research and evidence. Evidence for particular conditions is on Probiotics for specific needs: strain names in trials.
Frequently asked questions
Why does one study say probiotics work and another says they do not?
They often test different products in different people. NCCIH says different probiotics may have different effects. [1] Quality of the study also matters: one review found only 2 of 39 trials had low risk of bias across all domains. [5]
Did the large trials in children with gastroenteritis prove probiotics do not work?
No. Two trials of two different products found no difference from placebo for severity of gastroenteritis in young children in emergency departments. [6][7] They did not test other strains, adults or other conditions.
Is a bigger CFU number more likely to work?
Proper evidence not found in the sources we read. The two trials above used different study amounts, and both found no difference from placebo. [6][7] CFU is covered in CFU: what the number means.
Can a meta-analysis settle the question?
Only partly. Reviewers rate certainty down for inconsistency, indirectness, imprecision and bias, and pooling different strains can hide differences. [5]
Should I follow the result of one trial?
Use it as one piece of evidence about the exact product, amount and group studied. For your own situation, a clinician or pharmacist can weigh it with your health and medicines.
More details: evidence, limits and cautions
The details behind this page: cautions, limits of the evidence and where sources disagree. Open any note to read it.
Safety and who should ask a clinician
References
- NCCIH (US National Center for Complementary and Integrative Health). Probiotics: Usefulness and Safety. Page last updated August 2019 as shown on the page. Read 2026-10-23.
- US Food and Drug Administration. FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. News release, 2023. Read 2026-10-23.
- Donovan SM, et al. Establishing and Evaluating Health Claims for Probiotics. Adv Nutr. 2012;3(5):723-725. Symposium report; full text read 2026-10-23.
- Hill C, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014. Full text read 2026-10-23.
- Preidis GA, et al. AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):708-738. Full text read 2026-10-23.
- Schnadower D, et al. Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. N Engl J Med. 2018;379(21):2002-2014. Abstract read 2026-10-23.
- Freedman SB, et al. Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis. N Engl J Med. 2018;379(21):2015-2026. Abstract read 2026-10-23.